Key result
Preoperative IMRT for retroperitoneal sarcoma shows ~51% overall and local recurrence-free survival at five years.
Why the study?
Does preoperative IMRT improve overall survival and local recurrence free survival in patients with retroperitoneal sarcoma?
Population
21 patients with primary or recurrent retroperitoneal sarcomas (RSTS) treated between 2005 and 2011
Design
Cohort
Follow-up
5 years
Authors
Loading...
Should not yet change practice for retroperitoneal sarcoma; leaves open survival benefit versus surgery alone and supports randomized trials.
Cohort (n=21)
Does preoperative IMRT improve overall survival and local recurrence free survival in patients with retroperitoneal sarcoma?
Preoperative IMRT for retroperitoneal sarcoma is well tolerated, though local recurrences remain common, indicating potential need for dose escalation.
El-Bared et al. (2013) conducted a cohort in Retroperitoneal sarcoma (n=21). Preoperative intensity modulated radiation therapy (IMRT) was evaluated on 5-year overall survival. Preoperative IMRT for retroperitoneal sarcoma was well tolerated and yielded a 5-year overall survival of 51% and 5-year local recurrence-free survival of 51%.
Synapse has enriched one closely related paper. Consider it for comparative context: